Treatment of Pediatric Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia with Obecabtagene autoleucel, a CD19-Directed Chimeric Antigen Receptor T-cell Therapy: Preliminary Findings from the Phase Ib/II CATULUS Trial